Drug
Tafasitamab-cxix
Important: Reactions below are the flagged terms from this drug’s
FAERS report history (min. 3 co-reports per term) — PRR/ROR indicate
disproportionality in spontaneous reporting, not causation.
Data from FDA FAERS via openFDA. Last recalculated: 2026-09-14.
| Reaction | Co-reports (a) | PRR | ROR | Signal | |
|---|---|---|---|---|---|
| 1 | Lymphoma | 166 | 252.9 | 310.0 | signal |
| 2 | Polyneuropathy | 29 | 57.1 | 58.9 | signal |
| 3 | Blood Lactate Dehydrogenase Increased | 38 | 55.8 | 58.2 | signal |
| 4 | Cytopenia | 26 | 50.9 | 52.4 | signal |
| 5 | Disease Progression | 239 | 47.4 | 64.3 | signal |
| 6 | Haematotoxicity | 10 | 25.2 | 25.5 | signal |
| 7 | Hepatitis C | 12 | 23.0 | 23.3 | signal |
| 8 | Urosepsis | 8 | 20.3 | 20.5 | signal |
| 9 | Covid-19 Pneumonia | 10 | 19.7 | 19.9 | signal |
| 10 | Thrombotic Microangiopathy | 8 | 19.3 | 19.5 | signal |
| 11 | Cytokine Release Syndrome | 15 | 18.4 | 18.7 | signal |
| 12 | Bacteraemia | 9 | 17.9 | 18.0 | signal |
| 13 | Cardiomyopathy | 11 | 17.4 | 17.6 | signal |
| 14 | Cytomegalovirus Infection | 12 | 16.9 | 17.1 | signal |
| 15 | Neoplasm Progression | 19 | 12.6 | 12.9 | signal |
| 16 | Metastases To Lung | 6 | 12.1 | 12.2 | signal |
| 17 | Ill-defined Disorder | 23 | 8.8 | 9.0 | signal |
| 18 | Malignant Neoplasm Progression | 37 | 8.5 | 8.8 | signal |
| 19 | Gastric Cancer | 6 | 5.5 | 5.5 | signal |